Compare VanEck Semiconductor ETF (SMH) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
VanEck Semiconductor ETF vs Sanofi SA — how do they compare? VanEck Semiconductor ETF trades at $603.33 (market cap $73.92B), while Sanofi SA trades at $40.07 (market cap $95.18B). The key difference: Sanofi SA is the larger of the two by market cap, and Sanofi SA pays a 6.01% dividend while VanEck Semiconductor ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Semiconductor ETF for 101 Days and Sanofi SA for 94 Days on average.
| SMH | SNY | |
|---|---|---|
Market Cap | $73.92B | $95.18B |
Volume | 11,050,892 | 2,995,646 |
52-Week High | $668.91 | $52.34 |
52-Week Low | $325.10 | $39.51 |
Typical Hold Time | 101 Days | 94 Days |
Sector | — | Health |
Enterprise Value | — | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SMH (VanEck Semiconductor ETF) trades at $606.82, down 2.91% over the past day amid broader market volatility. The ETF maintains a bullish technical signal with strong moving average support, though oscillators are neutral. Recent news highlights semiconductor sector strength, with SMH up approximately 69% year-to-date in 2026, outperforming many individual stocks like Nvidia. The fund provides diversified exposure to chip leaders, benefiting from AI-driven demand and industry consolidation.
Outlook remains positive given structural growth in AI and semiconductor demand, but risks include high concentration in top holdings, sensitivity to tech sector volatility, and geopolitical trade tensions. Investors should weigh the ETF's historical outperformance against potential reversion risks as valuations stretch.
Sanofi (SNY) trades at $40.23, up 0.07% with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong Q2 2026 earnings beat with EPS of $1.21 versus $1.10 expected, continuing a trend of exceeding expectations. Recent expansion of the immunology alliance with Regeneron adds potential for future growth through new antibody programs.
While valuation metrics appear reasonable with P/E of 22.14 and P/S of 1.77, projected 2026 net income decline to $4.0B (8.09% margin) raises concerns. Analyst consensus leans cautious with 44% buy ratings versus 52% hold, suggesting tempered optimism despite recent positive developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About VanEck Semiconductor ETF
The fund normally invests at least 80% of its total assets in securities that comprise the target index. The index includes common stocks and depositary receipts of US exchange-listed companies in the semiconductor industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a US exchange. The fund is non-diversified.
Read more on SMH →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
